Related Experiment Video
Updated: Feb 6, 2026

Zebrafish as a Model to Assess the Teratogenic Potential of Nitrite
Published on: February 16, 2016
Mutagenicity and teratogenicity studies of vitacoxib in rats and mice
Jianzhong Wang1,2, Feifei Sun1,2, Shusheng Tang1,2
1Department of Veterinary Pharmacology and Toxicology, College of Veterinary Medicine, China Agricultural University, Beijing 100193, People's Republic of China.
Abstract:
Vitacoxib is a new drug candidate for treatment of inflammation, pain and fever as selective cyclooxygenase-2 inhibitors. In the current study, the mice sperm abnormality, mammalian erythrocyte micronucleus and in vivo chromosome aberration, and teratogenicity in SD rats were evaluated. Vitacoxib did not cause an increase in the frequency of structural chromosome aberrations, nor did it produce an increase in the number of micro nucleated polychromatic erythrocytes at dose of 1250-5000 mg/kg body weight (BW). There were no toxicological signs observed in teratogenicity test in female SD rats at dose of 200-5000 mg/kg BW. Based on these results of these studies, vitacoxib does not appear to be observed mutagenicity and teratogenicity.
Insights
Vitacoxib, a selective cyclooxygenase-2 inhibitor, was evaluated for safety. Studies found no evidence of mutagenicity or teratogenicity in mice and rats at high doses, indicating a favorable safety profile for this anti-inflammatory drug candidate.
Area of Science:
- Pharmacology
- Toxicology
- Drug Development
Background:
- Selective cyclooxygenase-2 (COX-2) inhibitors are developed for treating inflammation, pain, and fever.
- Vitacoxib is a novel drug candidate targeting the COX-2 pathway.
Purpose of the Study:
- To assess the mutagenic and teratogenic potential of Vitacoxib.
- To evaluate the safety profile of Vitacoxib in preclinical models.
Main Methods:
- Mice sperm abnormality assay.
- Mammalian erythrocyte micronucleus test.
- In vivo chromosome aberration test.
- Teratogenicity study in Sprague Dawley (SD) rats.
Main Results:
- Vitacoxib did not increase structural chromosome aberrations in mice.
- No increase in micronucleated polychromatic erythrocytes was observed in mice.
- No toxicological signs were noted in SD rats during the teratogenicity testing.
Conclusions:
- Vitacoxib demonstrated no mutagenicity in the conducted assays.
- Vitacoxib exhibited no teratogenicity in Sprague Dawley rats.
- These findings support Vitacoxib's potential as a safe therapeutic agent for inflammatory conditions.
Related Concept Videos
Teratogenicity
Mutagenicity and Carcinogenicity
Case Studies
Imaging Studies I: Kidney, Ureter, and Bladder Studies
Longitudinal Studies
Observational Studies
There are three types of observational studies – Prospective, retrospective, and cross-sectional.
Prospective Study
Prospective studies, also known as longitudinal or cohort studies, are carried out by collecting future data from groups sharing similar characteristics. One...

